Humacyte (NASDAQ:HUMA) Shares Down 5.1% – Time to Sell?

Humacyte, Inc. (NASDAQ:HUMA)’s share price fell 5.1% during mid-day trading on Monday . The company traded as low as $4.26 and last traded at $4.26. 1,752,903 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 2,411,848 shares. The stock had previously closed at $4.49.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HUMA. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. Benchmark reaffirmed a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. TD Cowen reiterated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Thursday, November 21st. Finally, BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Humacyte has a consensus rating of “Buy” and a consensus target price of $13.00.

Humacyte Stock Performance

The stock’s 50-day simple moving average is $5.26 and its 200 day simple moving average is $6.18. The stock has a market capitalization of $553.78 million, a price-to-earnings ratio of -3.28 and a beta of 1.47. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the sale, the director now owns 3,677,262 shares in the company, valued at $23,350,613.70. This trade represents a 8.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the sale, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,014,998 shares of company stock valued at $9,725,449. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. nVerses Capital LLC bought a new stake in shares of Humacyte in the 2nd quarter worth $28,000. Concurrent Investment Advisors LLC bought a new position in shares of Humacyte in the third quarter worth approximately $75,000. Principal Financial Group Inc. bought a new position in Humacyte during the second quarter valued at approximately $83,000. FORA Capital LLC bought a new position in Humacyte during the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC purchased a new stake in shares of Humacyte during the second quarter valued at approximately $97,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.